<code id='528018375C'></code><style id='528018375C'></style>
    • <acronym id='528018375C'></acronym>
      <center id='528018375C'><center id='528018375C'><tfoot id='528018375C'></tfoot></center><abbr id='528018375C'><dir id='528018375C'><tfoot id='528018375C'></tfoot><noframes id='528018375C'>

    • <optgroup id='528018375C'><strike id='528018375C'><sup id='528018375C'></sup></strike><code id='528018375C'></code></optgroup>
        1. <b id='528018375C'><label id='528018375C'><select id='528018375C'><dt id='528018375C'><span id='528018375C'></span></dt></select></label></b><u id='528018375C'></u>
          <i id='528018375C'><strike id='528018375C'><tt id='528018375C'><pre id='528018375C'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:83972
          AdventHealth alleges in a new lawsuit that MultiPlan conspires with health insurers to keep out-of-network payments low. Adobe

          AdventHealth, a large religious-affiliated hospital system, has sued MultiPlan, alleging the company has worked with health insurers to create a “cartel” that systematically underpays hospitals and doctors for care that is delivered out of an insurance company’s network.

          AdventHealth claims it has “overwhelming direct evidence” that MultiPlan’s agreements with health insurance companies are anticompetitive, and that MultiPlan’s “multi-year, ongoing conspiracy” with insurers has shortchanged hospitals and doctors at least $19 billion per year. MultiPlan said in a statement it “believes this lawsuit has no merit and looks forward to disproving these baseless allegations.”

          advertisement

          The lawsuit pours fresh gasoline on the fraught relationships between hospitals and insurance companies. It also adds to the ongoing debate about how much providers should be paid if they don’t agree to be part of an insurance network.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Startup Neumora takes a novel depression drug to Phase 3
          Startup Neumora takes a novel depression drug to Phase 3

          AdobeNeumora,aprivatelyheldbiotechcompany,ismovingintothefinalphaseoftestingwithanoveltreatmentforde

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          Tome Biosciences co

          SuzanneKreiter/GlobestaffWATERTOWN—TheirbrainstormingbeganinanMITclassin2010whentheeagerundergradssh